clinical trial · NCT06110793
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Metastatic Breast CancerLenvatinibPembrolizumaFulvestrant
brief summary
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
started
Dec 29, 2023
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
May 13, 2026
official title
A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol